Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Allena Pharmaceuticals, Inc. (ALNA) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/07/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
09/02/2022 8-K Resignation/termination of a director
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/24/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/11/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
07/12/2022 8-K Quarterly results
07/11/2022 8-K Quarterly results
07/08/2022 8-K Quarterly results
07/05/2022 8-K Quarterly results
06/28/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
03/18/2022 8-K Other Events  Interactive Data
02/25/2022 8-K Quarterly results
02/02/2022 8-K Quarterly results
01/04/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Allena Pharmaceuticals Provides Clinical and Corporate Update"
12/23/2021 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statement...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"At Market Issuance Sales Agreement, between Allena Pharmaceuticals, Inc. and B. Riley Securities, Inc",
"Opinion of Goodwin Procter LLP with respect to the New ATM Prospectus Supplement",
"Opinion of Goodwin Procter LLP with respect to the New Warrant Prospectus Supplement"
11/10/2021 8-K Quarterly results
Docs: "Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress  ALLN-346, a first-in-class, non-absorbed, orally administered enzyme in development for the treatment of hyperuricemia and gout in the setting of advanced chronic kidney disease, receives Fast Track Designation from FDA  Two Phase 2a trials for ALLN-346 enrolling patients with gout and chronic kidney disease; initial data expected in Q1 2022  First interim analysis for URIROX-2 Phase 3 trial of reloxaliase for the treatment of enteric hyperoxaluria planned for Q1 2022  Registered direct offering completed in Q3 raising gross proceeds of $28.0 million"
09/29/2021 8-K Quarterly results
08/27/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
07/16/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registra...",
"Form of Common Stock Purchase Warrant",
"Form of Pre-Funded Common Stock Purchase Warrant",
"Opinion of Goodwin Procter LLP",
"Form of Securities Purchase Agreement",
"Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules July 14, 2021 NEWTON, Mass., July 13, 2021 - Allena Pharmaceuticals, Inc. , a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has entered into definitive agreements with several healthcare-focused institutional and accredited investors for the purchase and sale of 21,357,744 shares of the Company's common stock and warrants to purchase up to an aggregate of 10,678,872 shares of the Company's common stock, at a purchase price of $1.311 per share of common stock and associated warrant, in a registered direct offeri..."
07/13/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
Docs: "Allena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update"
04/07/2021 8-K Quarterly results
04/02/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Transition Agreement, by and between Allena Pharmaceuticals, Inc. and Edward Wholihan",
"Transition Agreement, by and between Allena Pharmaceuticals, Inc. and Edward Wholihan"
03/30/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
03/05/2021 8-K Quarterly results
02/02/2021 8-K Quarterly results
01/28/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Allena Pharmaceuticals, Inc. 2021 Inducement Equity Plan",
"Allena Pharmaceuticals, Inc. 2021 Inducement Equity Plan"
12/03/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered or to be registered pursuant to Section 12 of the Act. Title of each class Trading symbol Name of each exchange on which registered Common Stock, par value $0.001 per share ALNA The Nasdaq Global Select Market Indicate by check mark whether the registrant is an e...",
"Amended and Restated Underwriting Agreement, between Allena Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC",
"Opinion of Goodwin Procter LLP",
"Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering",
"Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million"
11/30/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Allena Pharmaceuticals Announces Initial Data from Phase 1 Trial of ALLN-346"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy